The U.S. Food and Drug Administration approved 2025-26 COVID-19 vaccines for anyone age 65 and older and any person 6 months and older who has at least one underlying health condition that increases ...
The IDSA released 2025 guidelines for treating mild to moderate COVID-19, emphasizing risk-based antiviral use to prevent ...
A recent study examines the association between COVID-19 infection and an increased risk of recurrence in breast cancer ...
The field of cardiothoracic transplants has faced unprecedented challenges due to the COVID-19 pandemic, particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results